15.06 0.00 (0.00%)
After hours: 4:49PM EDT
|Bid||14.50 x 1400|
|Ask||15.07 x 900|
|Day's Range||14.42 - 15.23|
|52 Week Range||11.83 - 33.44|
|Beta (3Y Monthly)||0.09|
|PE Ratio (TTM)||28.74|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.83|
WASHINGTON, Aug. 21, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, today announced that it has named Aranthan "AJ" Jones II as its Chief Corporate Affairs and Communications Officer and Joakim "Kim" Wijkstrom as its Chief Marketing Officer. "I am very pleased to welcome both AJ and Kim to Vanda's executive leadership team," said Dr. Polymeropoulos.
“We are deeply disappointed to have not received approval at this time, given our previous discussions with the FDA on this program,” said Dr. Mihael Polymeropoulos, Vanda’s president and CEO.
Vanda said Monday ahead of the market open the FDA has issued a complete response letter for its sNDA for Hetlioz in treating jet lag disorder. Hetlioz is one of the commercial products the company markets for the treatment of non-24-hour sleep-wake disorder — a serious, rare and chronic circadian rhythm disorder. The company submitted the regulatory filing based on a study which showed that jet lag disorder patients slept nearly three hours longer over the three nights following their transatlantic trip when treated with Hetlioz than they did when they were untreated.
WASHINGTON, Aug. 19, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that on August 16 2019, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of Jet Lag Disorder (JLD). As Vanda previously reported on May 23, 2018, JLD patients reported sleeping nearly three hours longer over the three nights following their transatlantic trip when treated with Hetlioz® than they did over the three nights following their untreated transatlantic trip, consistent with Vanda's jet lag simulation studies.
Small-cap biopharma Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has withstood the market-wide sell-off witnessed in early August, thanks to the second-quarter report the company issued July 31. The company also reiterated its net product sales guidance for the fiscal year 2019. Notwithstanding the strong quarterly report and subsequent bounce, Vanda shares are still down about 43% year-to-date.
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Clinical development progresses as the company’s shareholders and spectators watch for movement on another front: Its squabbles with the Food and Drug Administration.
Abiomed stock collapsed Thursday after the medical technology company lagged Wall Street's full-year guidance expectations by more than $20 million. Quarterly sales were also light.
Vanda (VNDA) delivered earnings and revenue surprises of 800.00% and 7.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Q2 2019 Total net product sales of $59.1 million , a 25% increase year over year - Q2 2019 Hetlioz® net product sales grew to $37.8 million , a 35% increase year over year - Vanda reiterates 2019 net ...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Vanda Pharmaceuticals Inc. (VNDA) filed a derivative complaint against the company's officers and directors for breaches of fiduciary duties, unjust enrichment, and waste of corporate assets beginning in November 2015. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders. If you suffered a loss as a result of Vanda's misconduct, click here.
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
Conference Call and Webcast to Follow WASHINGTON , July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2019 on ...
Vanda Pharmaceuticals Inc. disclosed a note from federal regulators that pointed to deficiencies in its latest application for approval for a jet lag disorder treatment — but said the regulators didn't offer any more specifics. The D.C. biotech had applied for Food and Drug Administration approval to expand the label for its existing drug, Hetlioz, to be able to treat jet lag disorder. The company has been selling Hetlioz on the market since it was approved in 2014 to treat non-24-hour sleep-wake disorder, and it has fast become the company's top-selling product.